Hepatology   

How do factors like the presence of varices, severity of coagulopathy, etc., play into your decision?

For example, anticoagulation for recent, significant PE or dual antiplatelet therapy for recent MI, but requiring urgent procedures such as biopsy of ...

Are there situations in which you would continue the possible offending agent with close monitoring?

How would your recommendation change if the patient has H63 homozygous mutation?

For example, someone needing a higher platelet count for dual antiplatelet agent use after coronary stent placement.